Systematic review of cytokines and growth factors for the management of oral mucositis in cancer patients

Single-Dose Palifermin Prevents Severe Oral Mucositis During Multicycle Chemotherapy in Patients With Cancer

(2013) Saroj Vadhan-Raj   ANNALS OF INTERNAL MEDICINE

Palifermin is efficacious in recipients of TBI-based but not chemotherapy-based allogeneic hematopoietic stem cell transplants

(2012) J D Goldberg et al.   BONE MARROW TRANSPLANTATION

Palifermin Reduces Severe Mucositis in Definitive Chemoradiotherapy of Locally Advanced Head and Neck Cancer: A Randomized, Placebo-Controlled Study

(2011) Quynh-Thu Le et al.   JOURNAL OF CLINICAL ONCOLOGY

Palifermin Decreases Severe Oral Mucositis of Patients Undergoing Postoperative Radiochemotherapy for Head and Neck Cancer: A Randomized, Placebo-Controlled Trial

(2011) Michael Henke et al.   JOURNAL OF CLINICAL ONCOLOGY

A 3-day short course of palifermin before HDT reduces toxicity and need for supportive care after autologous blood stem-cell transplantation in patients with multiple myeloma

(2010) G. Kobbe et al.   ANNALS OF ONCOLOGY

AG013, a mouth rinse formulation of Lactococcus lactis secreting human Trefoil Factor 1, provides a safe and efficacious therapeutic tool for treating oral mucositis

(2010) Silvia Caluwaerts et al.   ORAL ONCOLOGY

Therapeutic effect of recombinant human epidermal growth factor (rhEGF) on mucositis in patients undergoing radiotherapy, with or without chemotherapy, for head and neck cancer

(2009) Hong Gyun Wu et al.   CANCER

Prevention of Radiation-Induced Oral Mucositis after Adenoviral Vector-Mediated Transfer of the Keratinocyte Growth Factor cDNA to Mouse Submandibular Glands

(2009) C. Zheng et al.   CLINICAL CANCER RESEARCH

Recombinant human epidermal growth factor treatment of radiation-induced severe oral mucositis in patients with head and neck malignancies

(2009) J.P. HONG et al.   EUROPEAN JOURNAL OF CANCER CARE

Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Recombinant Human Intestinal Trefoil Factor Oral Spray for Prevention of Oral Mucositis in Patients With Colorectal Cancer Who Are Receiving Fluorouracil-Based Chemotherapy

(2009) Douglas E. Peterson et al.   JOURNAL OF CLINICAL ONCOLOGY

Use of palifermin for the prevention of high-dose methotrexate-induced oral mucositis

(2008) E. Schmidt et al.   ANNALS OF ONCOLOGY

Long-Term follow-up of a Phase I/II Randomized, Placebo-Controlled Trial of Palifermin to Prevent Graft-versus-Host Disease (GVHD) after Related Donor Allogeneic Hematopoietic Cell Transplantation (HCT)

(2008) John E. Levine et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Palifermin reduces incidence and severity of oral mucositis in allogeneic stem-cell transplant recipients

(2008) S Langner et al.   BONE MARROW TRANSPLANTATION

Treatment of oral mucositis after peripheral blood SCT with ATL-104 mouthwash: results from a randomized, double-blind, placebo-controlled trial

(2008) A Hunter et al.   BONE MARROW TRANSPLANTATION

Palifermin dose should be adjusted to different therapy regimens

(2008) M P M Verhagen et al.   BONE MARROW TRANSPLANTATION

Gut protection by palifermin during autologous haematopoietic SCT

(2008) J-E Johansson et al.   BONE MARROW TRANSPLANTATION

Keratinocyte growth factor is effective in the prevention of intestinal mucositis in patients with hematological malignancies treated with high-dose chemotherapy and autologous hematopoietic SCT: a video-capsule endoscopy study

(2008) P Tsirigotis et al.   BONE MARROW TRANSPLANTATION

The trefoil factor family – small peptides with multiple functionalities

(2008) S. Kjellev   CELLULAR AND MOLECULAR LIFE SCIENCES

American Society of Clinical Oncology Clinical Practice Guidelines: Opportunities and Challenges

(2008) Mark R. Somerfield et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Study of Palifermin and Concurrent Chemoradiation in Head and Neck Squamous Cell Carcinoma

(2008) David M. Brizel et al.   JOURNAL OF CLINICAL ONCOLOGY